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SCOPE OF ETHICAL ISSUES
INVOLVED IN HUMAN SUBJECTS RESEARCH
Human participant research is a crucial element in the devel-
opment and approval of new drugs, biologics, devices, and
procedures that seek to improve patient care. Participation in
clinical research is an important professional obligation for
cardiovascular practitioners. This involvement ranges from
study design and implementation as investigators to the critical
role of subject enrollment for all cardiovascular practitioners.
The conduct of such research is one of the highest callings of
the clinical researcher/practitioner and must be conducted
according to the highest standards of science and ethics. All
human subjects research should be conducted according to
such standards. Difficult issues continue to require awareness
and careful management. Some of these issues are examined in
this report; conflict of interest is the first of these. A conflict of
interest may exist when a secondary interest has the potential to
distort, or appear to distort, the integrity of judgment relative
to the primary interest. The Hippocratic tradition and the
principle of beneficence require that the physician always act in
the patient’s best interest. However, when the physician profits
both professionally and financially from the patient’s partici-
pation in a clinical trial, the situation may become ethically
tenuous for the involved physician. Conversely, information
derived from clinical trials improves patient care. Thus, pa-
tients may also benefit from participation in clinical trials. This
might mitigate, in part, the ethical dilemma just described.
Non-financial conflicts of interest. Physician-investigators
obtain a number of non-financial benefits from participation
in clinical research trials (1). Career advancement, fulfill-
ment of a desire to do good, an opportunity to publish in a
peer-reviewed journal, fame, invitations to present at na-
tional and international meetings, future success in obtain-
ing grant funding for research, prestigious research prizes,
professional accolades for obtaining a positive outcome from
a particular clinical trial, and a personal sense of worth—all
potentially accrue to the physician-investigator. Although
these non-financial incentives are not well known outside of
academia, they are well recognized within the academic
community.
Levinsky (2) has recently pointed out that the deaths of
three research participants in clinical trials were not related
to financial factors at all. These deaths all occurred at
prominent research universities and were apparently the
result of excessive zeal, inadequate research, and/or ethical
knowledge or training deficits on the part of the investigator
and/or his staff (2–5). Financial conflicts of interest are
easier for the public to understand. Non-financial conflicts
of interest, such as academic promotion and accolades, are
often more subtle and may require some thought and study
before they become evident. Levinsky (2) suggests that
committees charged with the review of experiments involv-
ing human subjects (Institutional Review Boards [IRBs])
should consider these non-financial conflicts of interest
during their deliberations. Additionally, investigators and
those responsible for oversight should be aware of this form
of conflict of interest and should bear it constantly in mind
during the conduct of a clinical trial.
Clinical trials involving human subjects are essential to
the advancement of medical science, but the ethical situa-
tion for a physician-investigator who is simultaneously in
charge of caring for the patient-subject is particularly
challenging. As noted, the physician may benefit in a
non-financial manner—for example, from enhanced repu-
tation, publications, and so forth. At the same time, the
physician who serves as a clinical investigator enhances his
or her own career and may occasionally benefit financially
from payments made to the physician or the physician’s
institution by the sponsor of the clinical trial. Thus, physi-
cians who act as both investigator and attending physician
for a patient are caught in a clear ethical dilemma. The
physician might subtly coerce or induce the patient to
participate in the trial for the physician’s personal benefit.
This same conflict of interest might also arise in daily
clinical practice where the physician profits from the care of
the patient (see Task Force 4).
Patients who participate in clinical trials, whether they
receive experimental treatment or if they are in a control
group, can benefit from meticulous attention to their care,
by learning more about their disease process, and poten-
tially, from the trial environment itself (6). Because results
of research usually apply more directly to those patient
groups included in the studies, it is especially important to
include subjects from all socio-economic strata and all
ethnic groups. Cardiovascular practitioners should consider
Journal of the American College of Cardiology Vol. 44, No. 8, 2004
© 2004 by the American College of Cardiology Foundation and the American Heart Association, Inc. ISSN 0735-1097/04/$30.00
Published by Elsevier Inc. doi:10.1016/j.jacc.2004.08.038
participation of their patients for these reasons, and because
this type of research is essential to advance care in the field.
The process of enrollment must be undertaken carefully. In
addition, a physician must not allow patients to assume,
incorrectly, that they will receive the experimental therapy
and not the control regimen or device being tested.
Physician-investigators may not disabuse their patients’
expectations in an overzealous attempt to increase enroll-
ment in the clinical trial. All physician-investigators should
bear these points in mind when explaining participation in
a clinical trial. This same care should apply to all those
recruiting for a clinical trial. These issues become particu-
larly complex in the setting of tertiary care centers, where
multiple individuals may be involved in recruiting patients
for clinical trials. Indeed, everyone involved in the recruit-
ment process must avoid overzealous recruiting with poten-
tial failure to inform the patient adequately concerning the
risks involved in the experimental intervention (7–9).
Throughout the clinical trial process, it is important that
the physician-investigator maintain a state of mind referred
to by ethicists as “equipoise.” During the initial discussions
with the patient, equipoise exists when the physician-
investigator accepts the concept of uncertainty about the
benefits of one treatment relative to the other. At the
analytic stage, equipoise exists when the investigator is
equally willing to accept a negative or a positive outcome
from a clinical trial. Because a positive outcome in a trial is
more likely to lead to reward, there is subtle but persistent
pressure on the physician-investigator to favor a positive
outcome. Such pressure should not lead to multiple re-
analyses of trial data in an attempt to state something
“positive” about the investigation.
Financial conflicts of interest. Financial relationships are
a highly controversial aspect of human research. This topic
must be addressed because of the potential for real or
perceived conflict of interest. Some physicians devote a
substantial portion of their professional life to clinical trial
work. For these individuals, a potential problem arises
because they derive substantial income from participation in
clinical trials. A cardiovascular practitioner may function
merely as a “recruiting agent” for large pharmaceutical or
device manufacturing companies. This practice is inappro-
priate and is not condoned as it deviates from the principle
of putting a patient’s best interest first. Nevertheless, enroll-
ing patients in clinical trials is critical to advancing cardio-
vascular care. Participation in trials requires extra time for
the cardiovascular practitioner, and this can impact usual
patient care flow. Despite these issues, cardiovascular prac-
titioners need to support clinical trial enrollment.
Some physicians are truly the most knowledgeable indi-
viduals available with respect to a specific drug or device. It
is thus not surprising that industry values the opinion and
intellectual assistance of such individuals. It is reasonable for
such clinician-investigators to be compensated appropriately
for their time and effort. At times, payment includes stock
options or even shares in a new company founded to exploit
a new drug or device. In the latter circumstance, the
potential financial rewards for the physician-investigator can
be substantial. A conflict of interest is clear when such
individuals participate in clinical trials of that new drug or
device. The physician has a financial stake in the successful
initiation, implementation, and outcome stemming from
this particular research protocol. At times, such induce-
ments have led physicians to abrogate their social contract
with patients, and the results of these ethical failures have
occasionally been catastrophic for patients.
Following the passage of the Bayh-Dole Act, academi-
cians were encouraged to transfer their discoveries to indus-
try so the advances could be made available to patients;
many academic investigators became integrally involved in
the development and testing of innovative biomedical prod-
ucts. The resulting conflicts of interest have attracted the
attention of clinical investigators, academic physicians, pro-
fessional organizations, the media, the federal government,
and the public, thereby leading to a number of editorials,
surveys, and task force reports dealing with these problems
(10–16). The recommendations from all of these commen-
taries and task force publications are in many ways similar.
For example, the threshold employed in most of these
documents, including the rules of the National Institute of
Health (NIH), defined a “significant” financial arrangement
as one that exceeds $10,000 (see Task Force 3).
THE ROLE OF THE IRB OR HUMAN
EXPERIMENTATION REVIEW BOARD IN
OVERSEEING RESEARCH INVOLVING HUMAN SUBJECTS
Four comprehensive publications dealing with the regula-
tion of human experimentation have emanated from the
Association of American Medical Colleges (AAMC) and
the Institute of Medicine within the last three years (13–
16). These reports explore the various potential and actual
conflicts of interest, financial and non-financial, that exist in
human experimentation in the U.S. today. Responsible Re-
search describes a systematic approach for improving human
subject protection during clinical research trials. A variety of
topics are thoroughly examined, including research ethics,
the role of the IRB, investigator conflicts of interest, and
national and local regulation of human experimentation.
Numerous recommendations are presented for improving
the current situation. Preserving Public Trust is a compre-
hensive review of the U.S. system of human subject research
protection (14). This latter text also suggests numerous
reforms for national accreditation and oversight of human
subjects review boards (IRBs). Highly prominent in this
document is the recommendation that research oversight be
expanded to include conflict of interest review by a process
independent of the IRB. Two AAMC reports, “Protecting
Subjects, Preserving Trust, Promoting Progress I—Policy
and Guidelines for the Oversight of Individual Financial
Interests in Human Subjects Research” (15) and “Protecting
Subjects, Preserving Trust, Promoting Progress II—
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Principles and Recommendations for Oversight of an Insti-
tution’s Financial Interests in Human Subjects Research”
(16), explore in great detail potential financial conflicts of
interest and ways to defend against inappropriate behavioral
responses to such conflicts.
THE ACCF/AHA CONSENSUS CONFERENCE
RECOMMENDATIONS CONCERNING THE
MANAGEMENT OF HUMAN SUBJECT RESEARCH
Physician-Investigator Responsibilities
1. Participation in clinical research is an important obliga-
tion for cardiovascular practitioners and is strongly
encouraged.
2. Physicians who participate in clinical research must be
familiar with both the experimental therapy to be tested
and the principles of human subject research.
3. The ACCF/AHA Consensus Conference strongly en-
courages cardiovascular practitioners to enroll patients
who are members of underrepresented groups in clinical
trials.
Conflicts of Interest
1. Transparency in all dealings with clinical trial subjects is
the cornerstone of management of investigator related
conflict of interest. Cardiovascular investigators in-
volved in the clinical trial must disclose their financial
conflicts of interest to potential subjects.
2. Investigators must disclose very specific and detailed
financial information as per the guidelines in Task Force
3 to the IRB overseeing the trial (13,15).
3. The ACCF/AHA Consensus Conference supports the
concept of limitations on the amount of financial
involvement that physician-investigators and collabora-
tors may have in a particular research project. Physician-
investigators/collaborators with a significant financial
relationship (excluding funding for the trial itself) with
the sponsor of a particular drug or device under inves-
tigation should not personally participate in clinical
trials involving these drugs or devices. Unique circum-
stances can be adjudicated through the IRB mechanism
for single-center studies (e.g., primary trial for new drug
or device). For multicenter studies, the steering/execu-
tive committee for the study should address issues of
financial involvement at the individual investigator level.
These financial limitations do not apply to employees of
the medical product industry.
Informed Consent
1. A trial investigator who is the physician of a potential
subject has a special obligation to provide full disclosure
of his or her role in the investigation. Because of the
vulnerable status of the patient in such circumstances, it
must be made clear that refusal to participate in the trial
will not affect current or future care.
2. The ACCF/AHA Consensus Conference supports ef-
forts to improve the process of trial enrollment, such as
use of a neutral third party (i.e., a research subject
advocate or an ombudsman) to observe the informed-
consent process and make recommendations for
improvement.
IRBs
1. The IRBs should focus on the ethical implications of
each and every human research protocol (14). Both
financial and non-financial potential conflicts of interest
should be addressed.
2. The ACCF/AHA Consensus Conference recommends
two separate but coordinated processes, one for the
protection of the experimental subjects and one for the
examination and management of potential conflicts of
interest (financial and non-financial) on the part of the
physician-investigator.
3. Investigators should be given ample opportunity to
rebut the presumption that they cannot participate in
the research due to the conflict of interest that has been
raised by the oversight process.
4. Advertising copy aimed at recruiting research subjects
should be examined carefully by the IRB to ensure that
potentially misleading statements are not included in
these ads.
5. Special care must be taken when obtaining informed
consent from children and their parents, particularly
children too young to comprehend the implications of
the suggested intervention. Parental and/or guardian
involvement is critical to this process. These same issues
apply to other vulnerable individuals including but not
limited to the homeless, prisoners, and the uninsured.
Data Analysis, Integrity, and Publication
1. All human subjects’ research, not limited to randomized
trials, and regardless of sample size, should have a plan
for monitoring data collection and subject safety.
2. Physician-investigators should not have a primary role
in data analysis of a clinical trial involving a drug or
device in which they have a major personal financial
interest. This does not apply to employees of the
medical products industry (see Task Force 2).
3. At the outset of a sponsored clinical trial involving an
experimental therapy, a contractual arrangement should
be in place to ensure that publication of the results will
not be unduly delayed or obstructed by the sponsor of
the trial (see Task Force 2).
WHEN DOES MODIFICATION OF A MEDICAL
OR SURGICAL PROCEDURE, DEVICE, OR
DRUG BECOME AN EXPERIMENTAL PROCEDURE?
The issue of subtle variations in drugs and devices that have
already been approved rising to the level of investigational
status is not clearly described in the regulatory literature.
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What level of modification is required before an original
submission of a new drug or device application is required?
Decisions regarding the point of transition from an ap-
proved entity to an investigational entity are usually indi-
vidualized for each product. For the physician who modifies
a procedure or a device for use in daily practice, the
following distinction is important: “When a clinician de-
parts in a significant way from standard or accepted practice,
the innovation does not, in and of itself, constitute research.
The fact that a procedure is experimental in the sense of
new, untested, or different, does not automatically place it in
the category of research. Radically new procedures of this
description should, however, be made the object of formal
research at an early stage in order to determine whether they
are safe and effective” (17).
With respect to the development of such new procedures
or devices from the point of view of the developer, some
guiding principles from the Food and Drug Administration
(FDA) document, Guidance for Industry, Providing Clinical
Evidence of Effectiveness for Human Drugs and Biological
Products (May 1998) provide an informative perspective.
The purpose of that guidance document was to articulate
the FDA’s thinking concerning the quantitative and quali-
tative standards for demonstrating effectiveness of drugs and
biologics. The guidance document also describes the evi-
dence necessary to support approval of a new use of an
existing drug.
In certain cases, effectiveness of an approved drug or
product for a new indication, or effectiveness of a new
product, may be adequately demonstrated without addi-
tional clinical efficacy trials. Ordinarily, this will be because
other types of data provide a way to apply the known
effectiveness to a new population or a different dose,
regimen, or dosage form. The following are examples of
situations in which effectiveness might be extrapolated from
efficacy data for another claim or product: bioequivalence,
modified-release dosage forms, or different dose regimens.
Single studies for new uses of an existing drug, device, or
procedure may be submitted as per the following examples:
different doses, regimens, or dosage forms where the rela-
tionship between blood concentration and response is less
well established; studies in other phases of the disease;
studies in other populations; studies in combination or as
monotherapy; studies in a closely related disease; studies in
a less closely related disease, but where the general purpose
of the therapy is similar; studies of different clinical end
points; and studies of different pharmacologic/patho-
physiologic end points. The Center for Devices and Radio-
logical Health offered an algorithm for submission of
evidence for approval of a device (18).
Post-marketing surveillance studies offer the opportunity
to submit evidence for a new indication for an existing
product. However, in a guidance document on discretionary
post-marketing study of pacemaker leads, the FDA has
pointed out that the definition of what constitutes a distinct
entity versus a minor modification of an existing entity is
highly specific to a particular setting and should be individ-
ualized (19).
ISSUES PERTAINING TO
HUMAN SUBJECTS RESEARCH INVOLVING
SUBJECTS WITH COMPROMISED
CAPACITY FOR GIVING INFORMED CONSENT
Within cardiovascular medicine, clinical research may in-
volve individuals with limited capacity to grant informed
consent. Although no one contests or argues the critical
concept of informed consent, it must be recognized that in
the heart/brain injury domains there are several time-
sensitive situations in cardiovascular medicine where in-
formed consent may not be practical. These include cardiac
resuscitation, brain impairment from stroke, acute myocar-
dial infarction, and severe congestive heart failure. Other
vulnerable populations include children and those who are
mentally incapacitated. Although research in these popula-
tions may be difficult, investigation is particularly important
because of limited data to support therapeutic decision-
making (20).
Emergency research. Federally sanctioned guidelines allow
certain emergency and resuscitation human subjects re-
search to proceed without prospective informed consent
(20). The FDA regulations (21 CFR 50.24) provide a
narrow exception to the requirement for informed consent
from each human subject, or his or her legally authorized
representative, before initiation of an experimental interven-
tion. The exception applies to a limited class of research
activities involving human subjects who are in need of
emergency medical intervention but cannot give informed
consent because of their life-threatening medical condition,
and/or who do not have a legally authorized person to
represent them in a timely fashion. The intent of the
regulations is to allow research on life-threatening condi-
tions for which available treatments are unproven or unsat-
isfactory and where it is not possible to obtain informed
consent, while establishing additional protections to provide
for safe and ethical studies (21 CFR 50.24).
The FDA recognizes that persons with life-threatening
conditions who can neither give informed consent nor
refuse enrollment are a vulnerable population. Also, the
FDA recognizes that the lack of autonomy and inability of
subjects to give informed consent requires additional pro-
tective procedures in the review, approval, and operation of
this research. The exception from the informed-consent
requirement permitted by the rule is conditional upon
documented findings by an IRB. For this group of patient
subjects, a case-by-case independent determination is re-
placed by the general concurrence of a licensed physician.
Readers are referred to the full text of the regulation and the
preamble for additional guidance (20).
Research in pediatric patients. Research in pediatric pa-
tients (younger than 21 years of age) represents a special
challenge because of issues in the informed-consent process,
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and because of limitations on the kind of research permitted
(21–24). Federal regulations limit clinical research in chil-
dren to that in which the risks are no greater than minimal;
no greater than a minor increase over minimal where the
research offers the potential to acquire new knowledge about
the child’s condition; or where the research offers a prospect
for direct benefit to the child. Research that involves greater
risk with no prospect of direct benefit to the child may only
be performed with permission of the U.S. Secretary of
Health and Human Services. Application of the risk and
benefit categories is subjective, and, therefore, researchers
and IRBs must be careful to ensure that appropriate research
is allowed while risk is avoided.
Depending on the level of development, a child may not
be competent to provide autonomous consent. Ethically, the
best interest of the child must always be considered most
important; therefore, one must be more careful to consult
with all relevant parties and not use only the standard of
autonomy applied in adult consent. For pediatric subjects,
what we call “informed consent” is usually a combination of
informed parental permission and assent of the child. In this
setting, the potential for influence by factors unrelated to
the best interest of the child, such as payment for partici-
pation, can significantly impact parental decision-making.
Therefore, pediatric researchers are particularly obligated to
strive for informed consent to the greatest extent possible.
For adolescents and young adults, the informed-consent
protocol applied to adults should be used (13,15,20,22,24).
Research in cognitively impaired subjects. Although no
specific regulations guiding research in cognitively impaired
subjects exist, a comprehensive report was prepared by the
National Bioethics Advisory Commission (25). Principles
involved in research in this group reflect the vulnerable
nature of these populations.
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